| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA689: Acalabrutinib for treating chronic lymphocytic leukaemia |
|
Medicine details |
|
| Medicine name | acalabrutinib (Calquence®) |
| Formulation | Capsule |
| Reference number | 3671 |
| Indication | Monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/11/2020 |
| NICE guidance | TA689: Acalabrutinib for treating chronic lymphocytic leukaemia |